Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
Yuichi Ikegami, View ORCID ProfileIkuo Inoue, View ORCID ProfileYasuhiro Takenaka, Daigo Saito, Mitsuhiko Noda, View ORCID ProfileAkira Shimada
doi: https://doi.org/10.1101/2020.05.16.20095307
Yuichi Ikegami
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDIkuo Inoue
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDYasuhiro Takenaka
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
bDepartment of Physiology, Graduate School of Medicine, Nippon Medical School, 1-25-16 Nezu, Bunkyo, Tokyo 113-0031, Japan
PhDDaigo Saito
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MDMitsuhiko Noda
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDAkira Shimada
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDData Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Posted May 22, 2020.
Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
Yuichi Ikegami, Ikuo Inoue, Yasuhiro Takenaka, Daigo Saito, Mitsuhiko Noda, Akira Shimada
medRxiv 2020.05.16.20095307; doi: https://doi.org/10.1101/2020.05.16.20095307
Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
Yuichi Ikegami, Ikuo Inoue, Yasuhiro Takenaka, Daigo Saito, Mitsuhiko Noda, Akira Shimada
medRxiv 2020.05.16.20095307; doi: https://doi.org/10.1101/2020.05.16.20095307
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (625)
- Anesthesia (162)
- Cardiovascular Medicine (2336)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11704)
- Forensic Medicine (10)
- Gastroenterology (693)
- Genetic and Genomic Medicine (3689)
- Geriatric Medicine (345)
- Health Economics (632)
- Health Informatics (2366)
- Health Policy (926)
- Hematology (340)
- HIV/AIDS (773)
- Medical Education (364)
- Medical Ethics (104)
- Nephrology (396)
- Neurology (3452)
- Nursing (195)
- Nutrition (520)
- Oncology (1802)
- Ophthalmology (533)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (231)
- Palliative Medicine (66)
- Pathology (444)
- Pediatrics (1021)
- Primary Care Research (415)
- Public and Global Health (6091)
- Radiology and Imaging (1256)
- Respiratory Medicine (821)
- Rheumatology (375)
- Sports Medicine (320)
- Surgery (396)
- Toxicology (50)
- Transplantation (171)
- Urology (144)